Climb Bio (CLYM) Equity Average (2020 - 2026)

Climb Bio has reported Equity Average for 7 years, with the latest figure at $154.3 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 23.86% year-over-year to $154.3 million; the trailing twelve-month figure through Mar 2026 stood at $154.3 million (down 23.86% YoY), and the FY2025 full-year result was $186.2 million, up 16.55% from the prior year.
• Equity Average for Q1 2026 stood at $154.3 million, down from $168.7 million in the prior quarter.
• The five-year high for Equity Average was $220.5 million in Q3 2024, with the low at $107.0 million in Q1 2024.
• Historically, Equity Average has averaged $155.3 million across 5 years, with a median of $154.3 million in 2026.
• Annual changes were most pronounced in 2022 — Equity Average jumped 572.89% — and 2026, when it declined 23.86%.
• Climb Bio's Equity Average stood at $131.5 million in 2022, then decreased by 17.38% to $108.7 million in 2023, then surged by 98.15% to $215.3 million in 2024, then slipped by 21.64% to $168.7 million in 2025, then decreased by 8.57% to $154.3 million in 2026.
• The last three Equity Average figures came in at $154.3 million (Q1 2026), $168.7 million (Q4 2025), and $181.4 million (Q3 2025), per Business Quant data.